Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Vps34 regulates myofibril proteostasis to prevent hypertrophic cardiomyopathy
Hirotaka Kimura, Satoshi Eguchi, Junko Sasaki, Keiji Kuba, Hiroki Nakanishi, Shunsuke Takasuga, Masakazu Yamazaki, Akiteru Goto, Hiroyuki Watanabe, Hiroshi Itoh, Yumiko Imai, Akira Suzuki, Noboru Mizushima, Takehiko Sasaki
Hirotaka Kimura, Satoshi Eguchi, Junko Sasaki, Keiji Kuba, Hiroki Nakanishi, Shunsuke Takasuga, Masakazu Yamazaki, Akiteru Goto, Hiroyuki Watanabe, Hiroshi Itoh, Yumiko Imai, Akira Suzuki, Noboru Mizushima, Takehiko Sasaki
View: Text | PDF
Research Article Cardiology Cell biology

Vps34 regulates myofibril proteostasis to prevent hypertrophic cardiomyopathy

  • Text
  • PDF
Abstract

Hypertrophic cardiomyopathy (HCM) is a common heart disease with a prevalence of 1 in 500 in the general population. Several mutations in genes encoding cardiac proteins have been found in HCM patients, but these changes do not predict occurrence or prognosis and the molecular mechanisms underlying HCM remain largely elusive. Here we show that cardiac expression of vacuolar protein sorting 34 (Vps34) is reduced in a subset of HCM patients. In a mouse model, muscle-specific loss of Vps34 led to HCM-like manifestations and sudden death. Vps34-deficient hearts exhibited abnormal histopathologies, including myofibrillar disarray and aggregates containing αB-crystallin (CryAB). These features result from a block in the ESCRT-mediated proteolysis that normally degrades K63-polyubiquitinated CryAB. CryAB deposition was also found in myocardial specimens from a subset of HCM patients whose hearts showed decreased Vps34. Our results identify disruption of the previously unknown Vps34-CryAB axis as a potentially novel etiology of HCM.

Authors

Hirotaka Kimura, Satoshi Eguchi, Junko Sasaki, Keiji Kuba, Hiroki Nakanishi, Shunsuke Takasuga, Masakazu Yamazaki, Akiteru Goto, Hiroyuki Watanabe, Hiroshi Itoh, Yumiko Imai, Akira Suzuki, Noboru Mizushima, Takehiko Sasaki

×

Figure 6

Loss of Vps34 abrogates degradation of K63-linked polyubiquitinated CryAB.

Options: View larger image (or click on image) Download as PowerPoint
Loss of Vps34 abrogates degradation of K63-linked polyubiquitinated CryA...
(A) Immunoblot to detect CryAB in the NP-40-insoluble fraction of heart lysates from mckCre-Vps34fl/fl (cVps34–/–) mice and littermate control (cVps34+/+) at the indicated age. Lamin A, loading control. Results are representative of 3 trials. (B and C) Detection of K63-linked polyubiquitinated CryAB (~40-kDa bands; arrows) in the cardiac insoluble fractions from cVps34–/– mice at P80 (n = 4). (B) Proteins were immunoprecipitated (IP) with anti-K63pUb (K63) Ab or control (Ctrl) IgG followed by immunoblotting (IB) with anti-CryAB Ab. (C) IP with anti-CryAB Ab or Ctrl IgG followed by IB with anti-K63pUb Abs. Results are representative of 3 trials. (D) Immunoblot to detect Myc-tagged CryAB in lysates of P19.CL6 cells that were mock transfected or transfected with Myc-tagged CryAB plus FLAG-tagged WT, K48R-, or K63R-ubiquitin. Ubiquitinated proteins were immunoprecipitated with anti-FLAG Ab and immunoblotted with anti-Myc Ab to detect Myc-tagged CryAB. Arrow, ~40-kDa band of ubiquitinated CryAB. Results are representative of 3 trials. (E) Immunofluorescence detection of CryAB (blue), desmin (green), and p62 (red) in mckCre-Vps34fl/fl (cVps34–/–) and Vps34fl/fl (cVps34+/+) left ventricular sections. Scale bars: 10 μm. Des, desmin. Results are representative of at least 10 specimens examined per group.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts